Vaximm AG's technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be adapted to target a wide range of cancer-related antigens. Vaximm's most advanced compound, VXM01, is in Phase I/IIa studies with data expected in early 2017.
Dr. Matthias Schroff was appointed CEO of Vaximm in September this year; previously he was CEO of Mologen AG,...








